Managing target primed reverse transcription-based (TPRT) CART immuno-oncology programs (in vivo CART and tLNP Extracorporeal Delivery) in early research into development phases through coordinating gene editing platform, cell discovery, plasmid and RNA reagent production, targeted LNP delivery, PD, business development, regulatory, clinical, and preclinical in vivo efforts for interdependent programs in a primarily remote working environment alongside Chief Technology Officer program lead.Driving clear decisions and execution of liver delivery and platform development proof of concept projects and programs for application towards rare genetic disease therapeutics and ensuring the execution of external collaborations through alliance management to further company aims.Creating regular forums for data sharing and executive strategy enabling efficient decision making, supplemented with risk identification and mitigation strategies, collaborative timelines, and thorough minutes and action tracking.Implemented Smartsheets, Thinkcell, Lucidchart, Microsoft Project, OnePager Pro, Sharepoint and ad hoc tools to a variety of programs.Founded TesserOUT, an internal employee resource group focused on LGBTQIA+ representation, support, and ensuring health and opportunity equality for building culture and bolstering recruitment.

Third employee at this biotechnology company. Support the entire preclinical research and drug development portfolio. Built and lead a multidisciplinary team that executes protein engineering/purification/production/analytics efforts, early discovery, and process development for preclinical nomination.✯ Lead a four-person scientist team in precision protein therapeutics R&D of large molecule biologics in CUE-100, CUE-200, autoimmune, NeoSTAT, and early discovery platforms (nearly 5,000 protein constructs) for applications in immuno-oncology and other disease models.✯ During COVID-19, transitioned to virtual project, program, and team management role to coordinate efforts of protein, immunology, and business development groups. Addressed obstacles associated with essential bench scientists working alongside fully remote management teams. ✯ Created and implemented electronic lab notebook, protein inventory, and workflow process management systems, which altogether formed the company’s first functional database.✯ Serve on the joint research committee for the LG Chem partnership, which coordinates experiments and guides preliminary efforts to build a quality Chemistry, Manufacturing, and Controls (CMC) process.✯ Supported collaboration deals with Merck (global pharma company) and LG Chem (Korean alliance partner), as well as the successful IPO in 2018. ✯ Present discoveries and represent the company at major industry conferences, including presenting posters and mentoring.

Continuously innovated methods to boost throughput to meet rising demand, expand support for new domain areas, and provide expert feedback to early design engineers for use in downstream experiments and functional characterization.Designed and performed analysis of lead constructs, reagent preparation, cellular production, protein purification, quality control, validation, and data workflow for project execution in coordination with in vitro and in vivo biology groups.

As one of only two research scientists at NHPRR (an NIH-funded research group), produced and distributed antibodies and fusion proteins for in vitro diagnostics and in vivo administrations. Created unique Hybridoma and CHO cellular and media optimizations.

Investigated novel methods of peripheral nerve, spinal cord, and vascular repair in animal models. Performed surgeries to expose, manipulate, and suture nerves, blood vessels, and muscles. Analyzed experimental effects using a variety of testing methodologies.

Under the supervision of Dr. Philip Starks in a microbiology laboratory, explored bacterial/fungal consequences and relationship with an invasive paper wasp. Executed assays to assess cryptic pathogenic vectors and antimicrobial activity of cultured actinomycetes.